Antibiotic Therapy for Mycobacterium Avium Complex Infection
(MAC2v3 Trial)
Trial Summary
What is the purpose of this trial?
NTM therapy consists of a multi-drug macrolide based regimen for 18-24 months. Treated patients frequently experience debilitating side effects, and many patients delay the start of antibiotic treatment due to these risks. Common side effects include nausea, diarrhea, and fatigue, and rare but serious toxicities include ocular toxicity, hearing loss, and hematologic toxicity. To date, most of the evidence underlying the current treatment recommendations has come from observational studies in which either a macrolide has been combined with rifampin and ethambutol, or in some cases combined with ethambutol alone. The proposed study will answer whether a third drug is necessary or whether taking two drugs can increase tolerability without a substantial loss of efficacy.
Research Team
Kevin L Winthrop, MD, MPH
Principal Investigator
Oregon Health and Science University
Emily Henkle, PhD, MPH
Principal Investigator
Oregon Health and Science University
Eligibility Criteria
This trial is for adults over 18 who can consent and have a confirmed pulmonary Mycobacterium Avium Complex (MAC) infection. It's not for those with severe lung damage, planned lung surgery, extensive prior MAC treatment, cystic fibrosis, organ transplants, unmanageable drug interactions, or HIV.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Azithromycin (Macrolide Antibiotic)
- Ethambutol (Antimycobacterial Agent)
- Rifampin (Antimycobacterial Agent)
Azithromycin is already approved in Canada for the following indications:
- Respiratory tract infections
- Skin and soft tissue infections
- Sexually transmitted diseases
- Toxoplasmosis
- Malaria
- Preterm prelabor rupture of membranes
Find a Clinic Near You
Who Is Running the Clinical Trial?
Kevin Winthrop
Lead Sponsor
Kaiser Permanente Hawaii
Collaborator
Johns Hopkins University
Collaborator
Theodore DeWeese
Johns Hopkins University
Chief Executive Officer since 2023
MD from an unspecified institution
Allen Kachalia
Johns Hopkins University
Chief Medical Officer since 2023
MD from an unspecified institution
University of Iowa
Collaborator
Dr. Afable
University of Iowa
Chief Medical Officer since 2005
MD from Loyola Stritch School of Medicine, MPH from the University of Illinois
Joel Harris
University of Iowa
Chief Executive Officer since 2023
B.A. in Economics from the University of Iowa, Post-baccalaureate Certificate in Narrative Communications from Northwestern University
University of North Carolina
Collaborator
Michael O'Rand
University of North Carolina
Chief Executive Officer since 2022
PhD in Biology from Temple University
Dr. Miller
University of North Carolina
Chief Medical Officer since 2024
MD from Albert Einstein College of Medicine
Columbia University
Collaborator
Dr. Katrina Armstrong
Columbia University
Chief Executive Officer
MD from Johns Hopkins University, MS in Epidemiology from Harvard School of Public Health
Dr. Katrina Armstrong
Columbia University
Chief Medical Officer
MD from Harvard Medical School
Mayo Clinic
Collaborator
Dr. Gianrico Farrugia
Mayo Clinic
Chief Executive Officer since 2019
MD from University of Malta Medical School
Dr. Richard Afable
Mayo Clinic
Chief Medical Officer
MD from Loyola Stritch School of Medicine
Temple University
Collaborator
Dr. Kumar Budur
Temple University
Chief Medical Officer
MD, MS
Dr. Jeffrey M. Dayno
Temple University
Chief Executive Officer
MD from Temple University School of Medicine
University of California, San Diego
Collaborator
Dr. Christopher Longhurst
University of California, San Diego
Chief Medical Officer since 2021
MD and MS in Medical Informatics from UC Davis
Patty Maysent
University of California, San Diego
Chief Executive Officer since 2016
MBA from Stanford University
Loma Linda University
Collaborator
Adrian Cotton
Loma Linda University
Chief Medical Officer since 2020
MD
Richard H. Hart
Loma Linda University
Chief Executive Officer since 2015
MD, DrPH